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Notable Cases
snake are both “elapid” snakes (members of
the family Elapidae), characterised by
venom-secreting fangs that are fixed at the
front of the upper jaw. The RSS inhabits
temperate and tropical coastal regions and
has previously been identified between
northern New South Wales and south-east-
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Objective:  To describe demographic, geographical and clinical features of envenoming 
by the rough-scaled snake (RSS) (Tropidechis carinatus).
Design, setting and participants:  Prospective cohort study of RSS snakebite victims, 
recruited between January 2004 and December 2008, as part of the Australian Snakebite 
ct. RSS envenoming cases were confirmed by snake identification and/or venom-
ific enzyme immunoassay.
 outcome measures:  Clinical and laboratory features of envenoming.
lts:  There were 24 confirmed cases of RSS envenoming, nearly all occurring in 
tal areas between northern New South Wales and south-eastern Queensland. 
ty-three patients had local bite-site effects and 17 had at least three non-specific 
mic effects (eg, nausea, headache). All 24 had venom-induced consumption 
coagulopathy (VICC), and 19 had an international normalised ratio > 3.0. Six had 
bleeding from the bite site or intravenous cannula site, 10 had blood detected on 
urinalysis, and one had a major intra-abdominal haemorrhage. Mild neurotoxicity 
developed in two patients, and one patient developed myotoxicity with generalised 
myalgia, myoglobinuria and a peak creatine kinase level of 59 700 IU/L. Twenty-three 
patients were treated with antivenom (21 with tiger snake antivenom, two with 
polyvalent antivenom). Free venom was undetectable in 19 of 20 blood samples taken 
after antivenom administration.
Conclusion:  RSS envenoming occurs predominantly in coastal areas of northern NSW 
and southern Queensland, and within this range, most envenoming is due to the RSS 
rather than tiger snakes. Clinically it is characterised by VICC, with mild neurotoxicity and 
myotoxicity in some cases. Tiger snake antivenom appears to be effective against RSS 
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T  Australian snake Tropidechis cari-tus (the “rough-scaled snake”SS]) (Box 1) is a relatively small
owing to about 1 m in length) that
is taxonomically related to the Australian
tiger snake (Notechis spp). The RSS and tiger
ern Queensland, with a few specimens
found further north in Queensland.1,2 Fea-
tures of envenoming are thought to be simi-
lar to tiger snake envenoming, including
venom-induced consumption coagulopathy
(VICC), myotoxicity and neurotoxicity.
Snake venom detection kit (SVDK) testing
for RSS venom gives a positive result for
both RSS and tiger snake venom.3
Until recently, when an enzyme immu-
noassay (EIA) technique became available, it
was not possible to confirm RSS envenom-
ing unless a snake was provided for identifi-
cation. Previous reports have been from
snake handlers and botanists2 and may not
be representative of the general patient pop-
ulation being bitten by snakes. Further-
more, in northern NSW and south-eastern
Queensland, within the natural range of the
RSS, it remains unclear what proportion of
“tiger snake group” envenomings are due to
RSSs. As well as tiger snakes, two Hoploceph-
alus species (Stephens’ banded snake and
the pale-headed snake) occur in the same
region and their venoms may also test posi-
tive for tiger snake venom with SVDK.
1 The rough-scaled snake
Abbreviations
ASP Australian Snakebite Project
EIA Enzyme immunoassay
INR International normalised ratio
IQR Interquartile range
RSS Rough-scaled snake
SVDK Snake venom detection kit
VICC Venom-induced consumption 
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NOTABLE CASESThe aims of our study were to determine
the occurrence and features of RSS enven-
oming using expert identification of the
snake or EIA confirmation of venom in
patient sera.
METHODS
Patient cohort
We analysed a cohort of patients from north-
ern NSW and Queensland with potential
RSS bites or envenoming — defined by
snake identification, a positive SVDK result
in the tiger snake well, or any clinical or
laboratory features of elapid envenoming
without a diagnostic SVDK result. The
cohort was drawn from participants
recruited into the Australian Snakebite
Project (ASP).4 The ASP is an ongoing multi-
centre prospective observational study that
recruits suspected snakebite and snake
envenoming cases from over 100 major
tertiary and regional hospitals and associ-
ated major poisons information centres.
Ethics approval has been obtained from 16
human research ethics committees relevant
to all institutions involved.
Demographic details, clinical effects and
laboratory information and treatments relat-
ing to all patients recruited to the ASP are
recorded on datasheets made available to the
treating doctors. All data are entered into a
purpose-designed relational database.
Patients recruited to the ASP have serial
serum samples collected for venom and
antivenom quantification. Samples are spun,
aliquoted, frozen and stored at –80° C
before analysis.
From all patients recruited to the ASP
between January 2004 and December 2008,
a cohort was identified by searching the
database for “rough-scaled snake”, “tiger
snake group” and “tiger snake”. Suspected
tiger snake bites from areas clearly outside
the range of T. carinatus (ie, Western Aus-
tralia, South Australia, Tasmania and
Victoria) were excluded, as well as cases in
which there was a definite identification of a
tiger snake or a member of the genus Hoplo-
cephalus (Box 2). Finally, cases could only be
included if there was a blood sample avail-
able from the patient before antivenom was
administered or if the snake had been
brought in for identification. Definite RSS
envenoming was then confirmed by EIA
and/or identification of the snake by a quali-
fied expert.5
Testing procedure
EIA was performed on stored pre-antivenom
serum samples (or plasma samples, if no
serum was available), using a technique
described in detail elsewhere.6 In brief,
polyclonal antibodies (IgG) to RSS, common
tiger snake (N. scutatus) and Stephens’
banded snake (H. stephensii) were raised in
rabbits, conjugated to biotin and used to
develop a sandwich EIA using streptavidin-
horseradish peroxidase as the detecting
agent. The limits of detection were 0.3 ng/mL
for the anti-RSS assay and 0.7 ng/mL for the
anti-tiger snake assay. There was minimal
cross-reactivity between antibodies to
H. stephensii venom and antibodies to both
RSS and tiger snake venoms. There was
moderate cross-reactivity between RSS and
tiger snake venoms and antibodies, but
standard curves for each of these venoms
did not overlap within the variability of the
assay above 2 ng/mL. For concentrations
over 2 ng/mL, RSS and tiger snake venoms
could be accurately distinguished. Each
sample was tested for all three venoms.
Demographic, laboratory and 
clinical data
Data on people with confirmed RSS enven-
oming were extracted from the ASP data-
base. Information extracted included age,
sex, geographical location, snake identifica-
tion, SVDK results, clinical effects, labor-
atory investigations and antivenom
treatment. Symptoms and signs were classi-
fied as follows:
• Local bite effects: pain, swelling or bruis-
ing at the bite site.
• Non-specific systemic effects: nausea,
vomiting, headache, abdominal pain, diar-
rhoea or diaphoresis.
• VICC. This was defined as evidence of
complete consumption coagulopathy, indi-
cated by either an undetectable fibrinogen
level or a raised D-dimer level (at least 10
times above the assay cut-off point or
> 2.5 mg/L) associated with an international
normalised ratio (INR) > 3.0. Mild VICC
was defined as incomplete consumption
coagulopathy, characterised by a low but
detectable fibrinogen level or a raised D-
dimer level (above the assay cut-off point)
associated with a maximum INR between
1.5 and 2.5.
• Neurotoxicity. This was defined by ptosis,
external ophthalmoplegia, bulbar palsy,
respiratory muscle paralysis or limb para-
lysis.
• Myotoxicity. This was defined by local
or generalised myalgia and/or muscle
weakness in association with a creatine
kinase level > 1000 IU/L (reference range
[RR], 0–195 IU/L).
• Leukocytosis and lymphopenia. Leuko-
cytosis was defined as a white cell count
> 11.0  109/L (RR, 4.0–11.0  109/L), and
lymphopenia as a lymphocyte count
< 1.0  109/L (RR, 1.0–4.0  109/L).
Statistical analysis
For descriptive statistics, median and inter-
quartile range (IQR) were calculated for data
that were not normally distributed.
2 Flowchart showing the sample used in our study
ACT = Australian Capital Territory. SA = South Australia. Tas = Tasmania. Vic = Victoria. WA = Western 
Australia. * Sample positive for venom from either Notechis spp (tiger snake) or Tropidechis carinatus (RSS) 
but below the limit of venom detection to distinguish between the two venoms. † Three cases involving 
identified Notechis spp biting snake handlers and two cases in southern New South Wales outside the 
geographical range of T. carinatus. ◆
Australian Snakebite Project: 697 snakebite cases
78 cases of bites from “rough-scaled snake” (RSS), 
“tiger snake group” or “tiger snake”
42 suspected cases of RSS bite, 
based on geographical distribution
Outside geographical range of RSS: 
WA (9), SA (4), Vic (20), ACT (1), Tas (2)
Not RSS or unable to confirm RSS: 
no sample (5), positive for tiger snake or RSS* (7), 
Notechis spp† (5), Pseudonaja spp (1)
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NOTABLE CASESRESULTS
Of 697 people with snakebite recruited to
the ASP, 42 were identified as potential RSS
bite victims based on geographical location,
SVDK results and clinical effects. Of these
42 people, 24 were confirmed to have
experienced RSS envenoming, based on EIA
or definite snake identification (Box 2). EIA
results were available for 23 patients
(median venom concentration, 17 ng/mL
[IQR, 15–32 ng/mL]). The snake was identi-
fied and venom detected in serum in three
cases. In one case, confirmation was based
on snake identification alone, as no pre-
antivenom serum sample was available.
All RSS bites investigated in our study
occurred between Newcastle (mid-eastern
NSW) and the Sunshine Coast (south-east-
ern Queensland), except for one isolated
case in Cairns (northern Queensland) (Box 3).
The median age of the 24 patients was 35
years (IQR, 21–49 years; range, 9–60 years)
and 21 of the 24 patients were male. Based
on bite-site swabs tested with SVDK, 20
cases were positive for tiger snake venom,
two were negative and one was equivocal (in
one case, the bite-site SVDK test was not
done). Of four urine samples tested by
SVDK, all were positive for tiger snake.
Twenty-three patients complained of local
bite effects, and 17 reported three or more
non-specific systemic effects (Box 4). In the
19 patients who had VICC, recovery of INR
to 2.0 or less took a median time of 11.5
hours (IQR, 10.0–13.4 hours). The remain-
ing five patients had mild VICC. Six patients
complained of either bleeding from the bite
site or from an intravenous cannula site, and
10 had blood detected on urinalysis. One
patient had an intra-abdominal haemor-
rhage requiring blood transfusion but not
surgical intervention. Factor studies demon-
strated specific deficiencies in fibrinogen,
factor V and factor VIII, and partial reduc-
tion in factor II.
Neurotoxicity occurred in only two
patients and was mild, with only ptosis
developing. One of these patients also
developed significant myotoxicity with gen-
eralised myalgia and myoglobinuria. His
creatine kinase level peaked at 59 700 IU/L,
but he did not develop renal impairment.
Another two patients had a small rise in
creatine kinase level, peaking at 1790 IU/L
in both cases. Local myalgia was reported in
a further three patients and generalised
myalgia in another two. The only other
significant laboratory results were leukocy-
tosis in 22 patients, of whom 12 had lym-
phopenia. One patient had lymphopenia in
the absence of leukocytosis. There were no
deaths, and all patients were discharged
from hospital without sequelae.
Twenty-three patients were treated with
antivenom (21 with tiger snake antivenom,
two with polyvalent antivenom; total
median dose, 3 vials [IQR, 2–4 vials]), and
two patients received fresh frozen plasma.
Post-antivenom blood samples were avail-
able for 20 of the 23 patients receiving
antivenom. In 19 of these patients, no free
venom was detected after a median first
dose of 2 vials (IQR, 1.5–4 vials), and in five
patients, free venom was undetectable after
administration of only 1 vial. In one patient
who was given only a small amount of 1 vial
(due to an allergic reaction), venom was still
detectable after antivenom had been given.
DISCUSSION
The clinical effects of RSS envenoming
included VICC, which was severe in most
cases and associated with non-specific sys-
temic symptoms — most commonly head-
ache, nausea and abdominal pain. Major
bleeding occurred in one case, and signifi-
cant myotoxicity along with mild neurotox-
icity occurred in only one case.
RSS venom contains presynaptic and
postsynaptic neurotoxins, myotoxins and a
prothrombin activator that causes VICC.1
The RSS prothrombin activator is structur-
ally and functionally similar to human factor
Xa and belongs to the same group of pro-
thrombin activator toxins as those produced
by Notechis and Hoplocephalus spp.7
Most previous reports of RSS envenoming
have been anecdotal cases involving identi-
fied snakes or cases occurring within the
range of the RSS and shown to be SVDK-
positive for tiger snake venom, and thus
assumed to be the result of RSS bites. Trinca
and colleagues2 reported 12 confirmed RSS
bites in humans, but provided limited
details on the clinical effects. Of the 12
patients, one died within 5 minutes of the
3 Distribution of bites by the 
rough-scaled snake (Tropidechis 
carinatus) (triangles) compared 
with origin of T. carinatus 
specimens collected by the 
Queensland Museum (crosses)
4 Clinical features of rough-scaled 
snake envenoming
Clinical feature
Number 
of cases
Bite-site swab positive for tiger 
snake venom using SVDK
20
Local bite-site effects 23
Pain 23
Swelling 16
Bruising 9
Three or more non-specific 
systemic symptoms
17
Nausea 21
Vomiting 12
Headache 20
Abdominal pain 14
Diarrhoea 2
Diaphoresis 7
VICC or mild VICC 24
INR > 3.0 19
External bleeding 6
Bleeding from bite site 3
Bleeding from intravenous 
cannula site
3
Intra-abdominal bleed 1
Blood detected on urinanalysis 10
Neurotoxicity 2
Myotoxicity 3
Leukocytosis 22
Lymphopenia 13
INR = international normalised ratio. SVDK = snake 
venom detection kit. VICC = venom-induced 
consumption coagulopathy. ◆MJA • Volume 191 Number 3 • 3 August 2009 185
NOTABLE CASESbite and nine had non-specific systemic
symptoms, including headache, nausea,
vomiting, abdominal pain and diaphoresis.
There was no information on whether coag-
ulopathy occurred, and insufficient clinical
detail to determine whether significant myo-
toxicity or neurotoxicity occurred. Almost
no laboratory testing was done.
Other reports include possible RSS bites
that occurred within the known range of the
snake and were positive for tiger snake
venom with SVDK.3,8,9 Other larger series of
snake envenoming from Queensland are
likely to include cases involving T. carinatus,
but these cannot be distinguished from
other cases involving snakes testing positive
for tiger snake venom with SVDK.10-12 Myo-
toxicity and neurotoxicity have been
reported in all these cases, but without
confirmation by snake identification they
provide limited useful information on RSS
envenoming.
The clinical and laboratory effects of RSS
envenoming appear to be similar to those of
tiger snake envenoming.13,14 Although our
series was too small to determine whether
RSS envenoming is similar in the severity
and frequency of its effects, all major effects
reported in tiger snake envenoming
occurred in our series of RSS bites, includ-
ing VICC, myotoxicity and neurotoxicity.
In our study, SVDK testing of bite-site
swabs was positive for tiger snake venom in
nearly all RSS cases, confirming that RSS
venom gives a positive result for tiger snake
with SVDK. Conversely, of the cases of snake
envenoming occurring within the geograph-
ical range of RSS and testing positive for
tiger snake venom with SVDK, the majority
(24 of 31 cases) were in fact RSS envenom-
ing cases (Box 2).
The measurement of venom concentra-
tions in patient serum samples allowed us to
determine whether antivenom was effective
in binding all venom that was present. We
found that tiger snake antivenom binds RSS
venom and appears to be effective in
patients, even at lower doses than currently
recommended.
A limitation of our study was that we
could only include envenomed patients in
the cohort because the venom assay relies on
the detection of venom in blood. The study
is therefore likely to be biased towards more
severe cases, and we were unable to estab-
lish the envenoming rate for RSS (ie,
number of cases of envenoming divided by
number of definite bites).
Our study suggests that most, and poten-
tially all, tiger snake SVDK-positive cases in
northern NSW and south-eastern Queens-
land are likely to be due to RSS and that the
envenoming syndrome is similar to that of
Notechis spp. Tiger snake antivenom appears
to bind all venom, even after administration
of a single vial.
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